{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urticaria/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field f597ecce-bd6e-48f9-85af-04b1db1682bb --><h2>Update</h2><!-- end field f597ecce-bd6e-48f9-85af-04b1db1682bb -->","summary":null,"htmlStringContent":"<!-- begin item 0c829168-195e-48f9-955d-ef8d4309c080 --><!-- end item 0c829168-195e-48f9-955d-ef8d4309c080 -->","topic":{"id":"bfdbbcbf-5a56-51b8-b0aa-78a059b4cfec","topicId":"73ccd3ba-b5a5-4a3c-98b2-d838dd8a3c58","topicName":"Urticaria","slug":"urticaria","lastRevised":"Last revised in March 2020","chapters":[{"id":"7068e840-7bdb-5596-a56f-1c930bd4b8c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d6e4cfbd-5e36-5755-a780-8091e4b5f146","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9dde1c08-758f-55bb-b187-0203ded94048","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes"},{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update"}]},{"id":"5cff12c3-445b-5613-bf5d-dc48effe6502","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9abed54c-a9ed-58d4-bfce-3f0dddd49698","slug":"goals","fullItemName":"Goals"},{"id":"c2f713b4-e2ec-5e5e-be8f-5c4285be0b6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e829abf6-8412-500f-9425-647958addf97","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"92b040fe-6318-560a-9ae0-6f98a6aa9c09","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2d2f38df-88c4-5895-915d-199eefc9b02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d51180cd-461f-58ad-8f03-20d63965abfb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7fce165-b445-5aa6-9ec9-6ec8016f4bee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5d17f35-ddfe-5931-bfe4-b7dc039baea0","slug":"definition","fullItemName":"Definition"},{"id":"90888c1e-cd37-5fdf-9d0d-b71e51bf56c3","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"76d2cc5e-4a3e-5032-8eed-d4010ace1ae7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"507a6931-af71-54ae-a8e7-2b4393c2a41b","slug":"complications","fullItemName":"Complications"},{"id":"091f4740-5801-5ac0-83bd-a7ebbc2a2848","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fc3a9cf3-3dd4-5456-94e1-90c38c83a0b1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"513fb45b-36c0-59b5-8f88-13b10509caee","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e2100cac-0eb7-55e6-b138-9cbc110f1b71","slug":"investigations","fullItemName":"Investigations"},{"id":"2da7bf77-7798-5632-97d4-64d5463f8cde","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","fullItemName":"Management","slug":"management","subChapters":[{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria"}]},{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines"},{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines"},{"id":"b8336773-e3de-5ec0-a85b-93fd72ff7869","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"c88fe5a9-a559-5661-9a1f-e0ee93078a4d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e9950b4f-8af1-5d4b-b531-431ac4a731bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"729aa2a2-070b-51ed-9ecf-c29549914b66","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a30a2a17-7629-5022-a313-848d8264fb35","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6d1c75a-6a3d-5326-97ca-baff36370740","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dd5a897e-e7d5-5c98-88b6-35014f9a5dde","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d27a969-ded2-5d9d-9321-f65e47426edf","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d45859d-1b50-538f-84fa-568f43b5c283","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9dde1c08-758f-55bb-b187-0203ded94048","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"cec85dfc-9f2e-5b1f-8c32-197024ff5486","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 71c00dd5-4ccf-4898-9bb2-7993113ce81d --><h3>New evidence</h3><!-- end field 71c00dd5-4ccf-4898-9bb2-7993113ce81d -->","summary":null,"htmlStringContent":"<!-- begin item b2789e02-f464-46a9-a9f7-15505d4bd6c0 --><!-- begin field de499b7e-5208-4ad1-8ea1-9526ee7f3e40 --><h3>Evidence-based guidelines</h3><!-- end field de499b7e-5208-4ad1-8ea1-9526ee7f3e40 --><!-- begin field cb9b3dea-9419-48d9-9c0d-24be0db6c478 --><ul><li>Zuberbier, T., Aberer, W., et al (2018) The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. European Journal of Allergy and Clinical Immunology</li></ul><!-- end field cb9b3dea-9419-48d9-9c0d-24be0db6c478 --><!-- begin field 2f929059-8e5e-4be2-b5e8-3e0129b7811e --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 2f929059-8e5e-4be2-b5e8-3e0129b7811e --><!-- begin field 0ae70bff-5e58-4871-8d9c-bbb8df321379 --><p>No new HTAs published since 1 March 2017.</p><!-- end field 0ae70bff-5e58-4871-8d9c-bbb8df321379 --><!-- begin field bd81eeb5-e486-406a-ad72-aca671839f29 --><h3>Economic appraisals</h3><!-- end field bd81eeb5-e486-406a-ad72-aca671839f29 --><!-- begin field 69178901-7699-4b00-a069-3865707fd216 --><p>No new economic appraisals relevant to England since 1 March 2017.</p><!-- end field 69178901-7699-4b00-a069-3865707fd216 --><!-- begin field ceb591ed-1a79-4ad9-97f8-70392d692438 --><h3>Systematic reviews and meta-analyses</h3><!-- end field ceb591ed-1a79-4ad9-97f8-70392d692438 --><!-- begin field 2535dd17-85bb-4074-add7-1be35ee394b8 --><p>No new systematic reviews since 1 March 2017.</p><!-- end field 2535dd17-85bb-4074-add7-1be35ee394b8 --><!-- begin field 7492780d-32f5-490a-b5b7-2d507e9c869a --><h3>Primary evidence</h3><!-- end field 7492780d-32f5-490a-b5b7-2d507e9c869a --><!-- begin field 1dff4684-8b52-4454-ad57-3702940eb3f5 --><p>No new randomized controlled trials published since 1 March 2017.</p><!-- end field 1dff4684-8b52-4454-ad57-3702940eb3f5 --><!-- end item b2789e02-f464-46a9-a9f7-15505d4bd6c0 -->","subChapters":[]},{"id":"3f1f744c-ca23-5018-9357-a885ae725252","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 8eff3318-01c5-4e00-9a48-5dbe2ff2b1a5 --><h3>New policies</h3><!-- end field 8eff3318-01c5-4e00-9a48-5dbe2ff2b1a5 -->","summary":null,"htmlStringContent":"<!-- begin item f04661f8-3623-4a06-b9b8-e1bcdf79de6b --><!-- begin field 9e4a8c4b-4aa5-48aa-9b45-97670447a6b8 --><p>No new national policies or guidelines since 1 March 2017.</p><!-- end field 9e4a8c4b-4aa5-48aa-9b45-97670447a6b8 --><!-- end item f04661f8-3623-4a06-b9b8-e1bcdf79de6b -->","subChapters":[]},{"id":"78717187-6617-56a7-b5a1-1d97c7a21a64","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field d5ebb22e-b226-45d3-b728-1442b0eae613 --><h3>New safety alerts</h3><!-- end field d5ebb22e-b226-45d3-b728-1442b0eae613 -->","summary":null,"htmlStringContent":"<!-- begin item 64a5f614-73e2-46c1-868d-740079900bf1 --><!-- begin field 900aec0e-a591-407d-8a01-e96ca677c653 --><p>No new safety alerts since 1 March 2017.</p><!-- end field 900aec0e-a591-407d-8a01-e96ca677c653 --><!-- end item 64a5f614-73e2-46c1-868d-740079900bf1 -->","subChapters":[]},{"id":"6082b4d6-08b3-5f25-a536-1ae710221f43","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 48b4b780-794e-470b-8e09-140e43cc34ba --><h3>Changes in product availability</h3><!-- end field 48b4b780-794e-470b-8e09-140e43cc34ba -->","summary":null,"htmlStringContent":"<!-- begin item ce8f9a7a-e7ed-4288-a6d0-1710505f45bc --><!-- begin field 2560a59a-b4c9-4d6e-bffb-42a56afcd37b --><ul><li>Bilastine 10 mg orodispersible tablets are non-sedating, long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity are licensed for use in children aged 6 to 11 years with body weight ≥20 kg for symptomatic treatment of allergic rhino-conjunctivitis (seasonal, perennial) and urticaria. See more <a href=\"https://www.medicines.org.uk/emc/product/11727/smpc\" data-hyperlink-id=\"1f8833aa-b065-4ef1-bdd6-ac4f00a6d1e0\">here</a>.</li><li>Bilastine 2.5 mg/mL oral solution is licensed for the symptomatic treatment of urticarial in children aged 6 to 11 years with a body weight of at least 20 kg. See more <a href=\"https://www.medicines.org.uk/emc/product/11725/smpc\" data-hyperlink-id=\"b5ca9530-5829-4ef1-9c3c-ac7500ff8b52\">here</a>.</li></ul><!-- end field 2560a59a-b4c9-4d6e-bffb-42a56afcd37b --><!-- end item ce8f9a7a-e7ed-4288-a6d0-1710505f45bc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}